Effects of direct thrombin or factor Xa inhibition on clot thrombogenicity in vitro: comparison of dabigatran with rivaroxaban and apixaban

被引：0
|
作者：
van Ryn, J. [1 ]
Kink-Eiband, M. [1 ]
Kuritsch, I [1 ]
Wienen, W. [2 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Drug Discovery Support, Biberach, Germany
[2] Boehringer Ingelheim GmbH & Co KG, Pulm Res, Biberach, Germany
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-181
引用
收藏
页码：687 / 688
页数：2
相关论文
共 50 条
  • [41] Rivaroxaban associates with factor Xa faster than apixaban: a potential explanation for their different effects on tests of coagulation
    Yeh, C.
    Dale, B.
    Leslie, B.
    Kim, P. Y.
    Fredenburgh, J. C.
    Hirsh, J.
    Eikelboom, J.
    Weitz, J., I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 556 - 556
  • [42] Factor Xa Inhibitor Antidote, Andexanet Alfa Differentially Reverses the Effects of Apixaban, Betrixaban, Edoxaban and Rivaroxaban
    Fareed, Jawed
    Hoppensteadt, Debra A.
    Jeske, Walter
    Tafur, Alfonso J.
    Zorriasateyn, Kambiz
    Ramacciotti, Eduardo
    Lewis, Bruce
    CIRCULATION, 2019, 140
  • [43] The influence of the direct factor Xa inhibitor rivaroxaban on two different thrombin generation assays in patients with thrombophilia
    Siegemund, A.
    Siegemund, T.
    Scholz, U.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 706 - 706
  • [44] An in vitro model studying the effects of rivaroxaban and dabigatran on clot formation in factor VIII-depleted plasma mimicking the plasma of hemophilia A patients
    Chan, H. W.
    Lee, F. M. H.
    Stevic, I
    Bery, L. R.
    Lau, K.
    Chan, A. K.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 196 - 196
  • [45] UTILITY OF CLOT WAVEFORM DATA IN PROTHROMBIN TIME ASSAY AS A MARKER OF ANTICOAGULANT EFFECTS BY DIRECT THROMBIN OR FACTOR XA INHIBITORS.
    Tokunaga, Naoki
    Nagai, Kojiro
    Inoue, Chihiro
    Inoue, Yusuke
    Akaiwa, Saki
    Yoshida, Hiroko
    Nakao, Takayuki
    Doi, Toshio
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 : 107 - 107
  • [46] Hypercoagulability in rats is increased by low doses of the direct thrombin inhibitor melagatran, but is reduced by the direct factor Xa inhibitor rivaroxaban
    Perzborn, E.
    Buetehorn, U.
    Fischer, E.
    Harwardt, M.
    Klages, M.
    Trabandt, A.
    EUROPEAN HEART JOURNAL, 2008, 29 : 828 - 829
  • [47] Effects of rivaroxaban, a novel, oral, direct Factor Xa inhibitor, on coagulation assays
    Samama, M. M.
    Fem, L. L.
    Guinet, C.
    Perzborn, E.
    Martinoli, J.
    Depasse, F.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 693 - 693
  • [48] Effects of rivaroxaban, a novel, oral, direct factor Xa inhibitor, on coagulation assays
    Samama, M. M.
    Le Flem, L.
    Guinet, C.
    Perzborn, E.
    Martinoli, J-L
    Depasse, F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 35 - 36
  • [49] Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays
    Samama, Meyer Michel
    Le Flem, Lena
    Guinet, Celine
    Perzborn, Elisabeth
    Martinoli, Jean-Luc
    Depasse, Francois
    BLOOD, 2008, 112 (11) : 1041 - 1042
  • [50] THE RELATIVE IMPORTANCE OF THROMBIN INHIBITION AND FACTOR-XA INHIBITION TO THE ANTITHROMBOTIC EFFECTS OF HEPARIN
    BUCHANAN, MR
    BONEU, B
    OFOSU, F
    HIRSH, J
    BLOOD, 1985, 65 (01) : 198 - 201
12345